Pfizer (NYSE:PFE) Vs. JNJ, LLY, MRK, ABBV, BMY, ZTS, HZNP, RPRX, JAZZ, and PRGO
Should you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Johnson & Johnson (JNJ), Eli Lilly and (LLY), Merck & Co., Inc. (MRK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), and Perrigo (PRGO). These companies are all part of the "pharmaceuticals" industry.
Pfizer vs.
Pfizer (NYSE:PFE) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, community ranking, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.
Pfizer has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500.
Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 3.8%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.4%. Pfizer pays out 70.3% of its earnings in the form of a dividend. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Pfizer has a net margin of 23.06% compared to Eli Lilly and's net margin of 22.71%. Eli Lilly and's return on equity of 119.12% beat Pfizer's return on equity.
Pfizer has higher revenue and earnings than Eli Lilly and. Pfizer is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.
64.9% of Pfizer shares are held by institutional investors. Comparatively, 81.7% of Eli Lilly and shares are held by institutional investors. 0.1% of Pfizer shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Pfizer presently has a consensus price target of $44.00, suggesting a potential upside of 6.49%. Eli Lilly and has a consensus price target of $259.06, suggesting a potential upside of 8.40%. Given Eli Lilly and's stronger consensus rating and higher possible upside, analysts clearly believe Eli Lilly and is more favorable than Pfizer.
Pfizer received 362 more outperform votes than Eli Lilly and when rated by MarketBeat users. Likewise, 72.52% of users gave Pfizer an outperform vote while only 71.58% of users gave Eli Lilly and an outperform vote.
In the previous week, Pfizer had 39 more articles in the media than Eli Lilly and. MarketBeat recorded 56 mentions for Pfizer and 17 mentions for Eli Lilly and. Pfizer's average media sentiment score of 0.24 beat Eli Lilly and's score of 0.08 indicating that Pfizer is being referred to more favorably in the media.
Summary
Eli Lilly and beats Pfizer on 12 of the 21 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip ChartPfizer (NYSE:PFE) vs. Its Competitors
Pfizer Competitors List
